Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
Authors
Bahlis, NizarCorso, A
Mugge, LO
Shen, ZX
Desjardins, P
Stoppa, AM
Decaux, O
De Revel, T
Granell, M
Marit, G
Nahi, H
Demuynck, H
Huang, SY
Basu, Supratik
Guthrie, TH
Ervin-Hayes, A
Marek, J
Chen, G
Facon, T
Issue Date
2017-11-01
Metadata
Show full item recordAbstract
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial investigating lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) vs melphalan, prednisone and thalidomide for 12 cycles (MPT) and Rd for 18 cycles (Rd18) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) showed that Rd continuous prolonged progression-free survival and overall survival compared with MPT. A subanalysis of the FIRST trial was conducted to determine the benefits of Rd continuous in patients with NDMM based on depth of response. Patients randomized 1:1:1 to Rd continuous, Rd18 or MPT were divided into subgroups based on best response: complete response (CR; n=290), ≥ very good partial response (VGPR; n=679), ≥ partial response (PR; n=1 225) or ≤ stable disease (n=299). Over 13% of patients receiving Rd continuous who achieved ≥ VGPR as best response did so beyond 18 months of treatment. Rd continuous reduced the risk of progression or death by 67%, 51% and 35% vs MPT in patients with CR, ≥ VGPR and ≥ PR, respectively. Similarly, Rd continuous reduced the risk of progression or death by 61%, 54% and 38% vs Rd18 in patients with CR, ≥ VGPR and ≥ PR, respectively. In patients with CR, ≥ VGPR or ≥ PR, 4-year survival rates in the Rd continuous arm (81.1%, 73.1% or 64.6%, respectively) were higher vs MPT (70.8%, 59.8% or 57.2%, respectively) and similar vs Rd18 (76.5%, 67.7% and 62.5%, respectively). Rd continuous improved efficacy outcomes in all responding patients, including those with CR, compared with fixed duration treatment.Citation
Bahlis, N. J., Corso, A., Mugge, L.-O., Shen, Z.-X. et al (2017) Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial, Leukemia, 31, pp. 2435–2442. DOI: 10.1038/leu.2017.111Publisher
Springer Science and Business Media LLCJournal
LeukemiaPubMed ID
28373701 (pubmed)Additional Links
https://www.nature.com/articles/leu2017111Type
Journal articleLanguage
enDescription
© 2017 The Authors. Published by Nature Publishing Group. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1038/leu.2017.111ISSN
0887-6924EISSN
1476-5551ae974a485f413a2113503eed53cd6c53
10.1038/leu.2017.111
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International
Related articles
- Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
- Authors: Bahlis NJ, Corso A, Mugge LO, Shen ZX, Desjardins P, Stoppa AM, Decaux O, de Revel T, Granell M, Marit G, Nahi H, Demuynck H, Huang SY, Basu S, Guthrie TH, Ervin-Haynes A, Marek J, Chen G, Facon T
- Issue date: 2017 Nov
- Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
- Authors: Lu J, Lee JH, Huang SY, Qiu L, Lee JJ, Liu T, Yoon SS, Kim K, Shen ZX, Eom HS, Chen WM, Min CK, Kim HJ, Lee JO, Kwak JY, Yiu W, Chen G, Ervin-Haynes A, Hulin C, Facon T
- Issue date: 2017 Mar
- Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
- Authors: Belch A, Bahlis N, White D, Cheung M, Chen C, Shustik C, Song K, Tosikyan A, Dispenzieri A, Anderson K, Brown D, Robinson S, Srinivasan S, Facon T
- Issue date: 2020 Dec
- Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
- Authors: Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T
- Issue date: 2016 Oct 20